Cathie Wood-run Ark Invest on Friday picked up shares of a biopharma companyafter it revealed significant progress with it weight-loss drug candidate. What Happened: Ark, through its ARK Genomic Revolution ETF (CBOE: ARKG), bought 11,360 shares of Amgen, Inc. (NASDAQ:AMGN), which rallied nearly 12% on Friday. The purchase would have been worth $3.54 million. Following Friday’s purchase, Amgen’s weighting in ARKG stood at 1.06%, attributed to the 51,712 shares held by the exchange-traded fund. See Also: Best ETFs To Buy Right Now Why It’s Important: Amgen reported a double beat Thursday after t…
